Table 3.
Comparison of surgery versus no surgery patients
| Variable | Surgery | No Surgery | P value⁎ | |
|---|---|---|---|---|
| Total | 28 | 15 | ||
| Age (mean [SD]) | 62.36 (8.69) | 66.47 (12.88) | .220 | |
| Sex (n [%]) | Female | 13 (46.4) | 6 (40.0) | .934 |
| Male | 15 (53.6) | 9 (60.0) | ||
| Location (n [%]) | Body/tail | 3 (10.7) | 1 (6.7) | 1.000 |
| Head | 25 (89.3) | 14 (93.3) | ||
| BRPC factor (n [%]) | Lymph node | 4 (14.3) | 0 (0.0) | .324 |
| Vascular | 24 (85.7) | 15 (100.0) | ||
| Pre CA19-9 (mean [SD]) | 657.79 (1620.34) | 2318.33 (3980.92) | .059 | |
| Post CA19-9 (post CT) (mean [SD]) | 161.04 (222.56) | 728.36 (1231.88) | .034 | |
| Post CA19-9 (post CR) (mean [SD]) | 43.93 (46.10) | 1056.14 (2270.93) | .091 | |
| CA19-9 change (mean [SD]) | − 594.58 (1723.64) | − 1457.55 (2685.42) | .259 | |
| % CA19-9 change (mean [SD]) | − 0.30 (0.90) | − 0.43 (0.83) | .695 | |
| Cycles (mean [SD]) | 4.59 (1.34) | 3.71 (2.67) | .166 | |
| NACR (n [%]) | 0 | 11 (40.7) | 4 (36.4) | 1.000 |
| 1 | 16 (59.3) | 7 (63.6) | ||
| NA chemo (n [%]) | FOLFIRINOX | 26 (96.3) | 11 (73.3) | .066 |
| FOLFIRINOX/GA | 0 (0.0) | 2 (13.3) | ||
| GA | 1 (3.7) | 2 (13.3) | ||
| NACR chemo (n [%]) | C | 6 (37.5) | 2 (28.6) | 1.000 |
| FU | 10 (62.5) | 5 (71.4) |
GA, gemcitabine/nab-paclitaxel; C, capecitabine; FU, 5-fluorouracil.
⁎
t test or χ2 test.